Media headlines about Medtronic (NYSE:MDT) have trended somewhat positive on Wednesday, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medtronic earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news articles about the medical technology company an impact score of 47.2360629750638 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Zacks: Brokerages Expect Medtronic PLC (MDT) Will Post Earnings of $1.11 Per Share (americanbankingnews.com)
- Medtronic (MDT) Scheduled to Post Quarterly Earnings on Tuesday (americanbankingnews.com)
- Report: New hack could put malware directly on Medtronic pacers, allow full control (massdevice.com)
- Becton, Dickinson Global Foothold Strong, Recalls Rampant (finance.yahoo.com)
- Medtronic (MDT) Upgraded to Strong-Buy at Needham & Company LLC (americanbankingnews.com)
Several research analysts recently weighed in on MDT shares. Zacks Investment Research cut shares of Medtronic from a “hold” rating to a “sell” rating in a research report on Tuesday, August 7th. Morgan Stanley upped their price objective on shares of Medtronic from $90.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, May 25th. Raymond James started coverage on shares of Medtronic in a research report on Thursday, May 31st. They issued an “outperform” rating and a $96.00 price objective on the stock. TheStreet upgraded shares of Medtronic from a “c+” rating to a “b-” rating in a research report on Monday, May 21st. Finally, Sanford C. Bernstein started coverage on shares of Medtronic in a research report on Wednesday, June 27th. They issued a “market perform” rating and a $88.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $93.24.
Medtronic (NYSE:MDT) last issued its quarterly earnings results on Thursday, May 24th. The medical technology company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.03. Medtronic had a net margin of 10.36% and a return on equity of 12.84%. The business had revenue of $8.14 billion for the quarter, compared to analysts’ expectations of $8 billion. During the same period last year, the business earned $1.33 earnings per share. The business’s quarterly revenue was up 2.9% on a year-over-year basis. sell-side analysts predict that Medtronic will post 5.11 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 25th. Shareholders of record on Friday, July 6th were given a dividend of $0.50 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.46. This represents a $2.00 dividend on an annualized basis and a yield of 2.20%. The ex-dividend date was Thursday, July 5th. Medtronic’s dividend payout ratio (DPR) is presently 41.93%.
In other Medtronic news, SVP Richard Kuntz sold 11,500 shares of the stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $87.13, for a total transaction of $1,001,995.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Bradley E. Lerman sold 8,910 shares of the stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $86.82, for a total transaction of $773,566.20. The disclosure for this sale can be found here. 0.31% of the stock is owned by company insiders.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Featured Story: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.